Lybalvi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar 1 disorder in adults. Lybalvi may be prescribed alone for short periods to treat manic or mixed episodes of bipolar 1 disorder. It may also be taken in combination with other drugs for maintenance treatment. Lybalvi is a combination of two drugs, olanzapine and samidorphan.
Olanzapine is an atypical antipsychotic, and samidorphan is an opioid antagonist. Lybalvi is believed to work by blocking the effects of dopamine and serotonin on certain parts of the brain involved in manic and mixed episodes of bipolar 1 disorder.
How do I take it?
Lybalvi is taken once a day. Lybalvi comes in tablet form.
The FDA-approved label for Lybalvi lists common side effects including weakness, dry mouth, constipation, sleepiness, dizziness, headache, and increased appetite.
Rare but serious side effects listed for Lybalvi can include diabetes, high blood sugar, seizures, cognitive impairment, elevated protein levels, neuroleptic malignant syndrome, sudden uncontrolled muscle movements, and low white blood cell counts. Lybalvi should not be taken by elderly people with dementia or by anyone who is also taking opioid drugs or currently experiencing opioid withdrawal.
For more details about this treatment, visit:
Lybalvi — Alkermes